Regentis Biomaterials (RGNT) Short term Debt (2024 - 2025)

Regentis Biomaterials (RGNT) reported Short term Debt of $1.2 million for Q4 2025, down 72.62% year-over-year from $4.4 million in Q4 2024, and down 72.62% quarter-over-quarter from $4.4 million in Q4 2024.

Regentis Biomaterials (RGNT) Short term Debt (2024 - 2025) Analysis & Trends

Regentis Biomaterials (RGNT) has 2 years of Short term Debt data on file, last reported at $1.2 million in Q4 2025.

  • Short term Debt for Q4 2025 came in at $1.2 million, down 72.62% year-over-year; the trailing twelve-month figure through Dec 2025 was $1.2 million (down 72.62% YoY), and the FY2025 annual result was $1.2 million, down 72.62% from the prior year.
  • Short term Debt retreated to $1.2 million in Q4 2025 per RGNT's latest filing, from $4.4 million in the prior quarter.
  • Over five years, Short term Debt peaked at $4.4 million in Q4 2024 and troughed at $1.2 million in Q4 2025.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Intuitive Surgical 148.09 Bn 143.69 Bn 1.83 Bn
2 Becton Dickinson 41.00 Bn 39.99 Bn 2.15 Bn
3 Medline 30.38 Bn 36.22 Bn 1.84 Bn
4 Resmed 28.22 Bn 26.56 Bn 890.98 Mn
5 West Pharmaceutical Services 23.72 Bn 23.19 Bn 296.40 Mn
6 Solventum 13.33 Bn 13.33 Bn 1.10 Bn
7 Cooper Companies 13.12 Bn 12.99 Bn 735.40 Mn
8 Align Technology 12.86 Bn 11.80 Bn 736.59 Mn
9 Baxter International 10.51 Bn 8.47 Bn 891.00 Mn
10 Regentis Biomaterials 3.72 Mn -3.66 Mn -

Historic Data

Download Data
DateValue
Dec 31, 2025 1.20 Mn
Dec 31, 2024 4.37 Mn